Cadrenal Therapeutics (CVKD) Accumulated Expenses (2022 - 2026)

Cadrenal Therapeutics has reported Accumulated Expenses for 5 years, with the latest figure at $240143.0 in Q1 2026.

• Quarterly Accumulated Expenses rose 5.53% year-over-year to $240143.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $240143.0 (up 5.53% YoY) and the FY2025 annual result came in at $733196.0, down 24.14% from the prior year.
• Accumulated Expenses fell to $240143.0 in Q1 2026 per CVKD's latest filing, from $733196.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $966575.0 in Q4 2024 and troughed at $227565.0 in Q1 2025.
• A 5-year average of $499290.7 and a median of $456369.5 in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 70.25% in 2024, then slumped 48.37% in 2025.
• Over 5 years, Accumulated Expenses stood at $863564.0 in 2022, then tumbled by 30.97% to $596131.0 in 2023, then surged by 62.14% to $966575.0 in 2024, then fell by 24.14% to $733196.0 in 2025, then sank by 67.25% to $240143.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $240143.0, $733196.0, and $471964.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.